Ignite Creation Date:
2024-05-05 @ 11:44 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00111449
Status:
COMPLETED
Last Update Posted:
2013-05-15
First Post:
2005-05-20
Brief Title:
Evaluating the Safety of Etanercept 50 mg Twice Weekly in Subjects With Psoriasis
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
A Phase 3 Multicenter Study to Assess the Efficacy and Safety of Etanercept 50 mg Twice Weekly in Psoriasis
Status:
COMPLETED
Status Verified Date:
2013-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the effect of etanercept 50 mg twice weekly compared to placebo over 12 weeks on the psoriasis area and severity index PASI in subjects with psoriasis This study will also evaluate the safety and tolerability of etanercept 50 mg twice weekly determine the effect of etanercept 50 mg twice weekly on patient reported outcomes PRO and characterize the pharmacokinetics PK profile of etanercept 50 mg twice weekly
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None